{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:43:52Z","timestamp":1772120632496,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.conctc.2020.100678","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T20:57:00Z","timestamp":1606510620000},"page":"100678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design"],"prefix":"10.1016","volume":"20","author":[{"given":"Miguel","family":"Sampayo-Cordero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat","family":"Miguel-Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"P\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel L.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garde-Noguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Holgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malfettone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2020.100678_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-16-0738","article-title":"18F-fluoromisonidazole PET and activity of neoadjuvant Nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial","volume":"23","author":"Quintela-Fandino","year":"2017","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.conctc.2020.100678_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.conctc.2020.100678_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jnci\/djr238","article-title":"More randomization in phase II trials: necessary but not sufficient","volume":"103","author":"Rubinstein","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.conctc.2020.100678_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1202-6","article-title":"Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases","volume":"14","author":"Sampayo-Cordero","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.conctc.2020.100678_bib5","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/sim.3997","article-title":"A proof of concept phase II non-inferiority criterion","volume":"30","author":"Neuenschwander","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib6","series-title":"FDA GUIDANCE: Non-inferiority Clinical Trials to Establish Effectiveness","author":"FDA","year":"2016"},{"key":"10.1016\/j.conctc.2020.100678_bib8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-11-1653","article-title":"Statistical issues and recommendations for noninferiority trials in oncology: a systematic review","volume":"18","author":"Tanaka","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.conctc.2020.100678_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cct.2015.02.007","article-title":"Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials","volume":"42","author":"Jung","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2020.100678_bib10","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon's two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/10543400600825645","article-title":"P-value calculation for multistage phase II cancer clinical trials","volume":"16","author":"Jung","year":"2006","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.conctc.2020.100678_bib13","series-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2016"},{"key":"10.1016\/j.conctc.2020.100678_bib14","author":"Seshan"},{"key":"10.1016\/j.conctc.2020.100678_bib15","author":"Oberle"},{"key":"10.1016\/j.conctc.2020.100678_bib16","author":"Potte"},{"key":"10.1016\/j.conctc.2020.100678_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1440-1681.2009.05288.x","article-title":"Confidence in Altman-Bland plots: a critical review of the method of differences","volume":"37","author":"Ludbrook","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.conctc.2020.100678_bib18","series-title":"Chapman and Hall\/CRC","article-title":"Randomized phase II cancer clinical trials","author":"Jung","year":"2013"},{"key":"10.1016\/j.conctc.2020.100678_bib19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.conctc.2020.100678_bib20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2020.100678_bib21","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2020.100678_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.breast.2014.06.017","article-title":"A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial","volume":"23","author":"Llombart-Cussac","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.conctc.2020.100678_bib25","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1158\/1078-0432.CCR-11-3252","article-title":"Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer","volume":"18","author":"Tang","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.conctc.2020.100678_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-12-117","article-title":"What inference for two-stage phase II trials?","volume":"12","author":"Porcher","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.conctc.2020.100678_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cct.2015.02.007","article-title":"Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials","volume":"42","author":"Jung","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2020.100678_bib29","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2020.100678_bib30","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2020.100678_bib31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice versus E7389) investigators, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2020.100678_bib33","doi-asserted-by":"crossref","first-page":"105972","DOI":"10.1016\/j.cct.2020.105972","article-title":"Keyboard design for phase I drug-combination trials","volume":"92","author":"Pan","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2020.100678_bib34","article-title":"Preoperative olaparib in early-stage endometrial cancer (EC): a phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)","volume":"36","author":"Romero","year":"2018","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.conctc.2020.100678_bib35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCO.0000000000000583","article-title":"Window of Opportunity trials for biomarker discovery in breast cancer.","volume":"31","author":"Arnedos","year":"2019","journal-title":"Curr. Opin. Oncol"},{"key":"10.1016\/j.conctc.2020.100678_bib36","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.ejca.2015.08.004","article-title":"Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome","volume":"51","author":"Monzon","year":"2015","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.conctc.2020.100678_bib37","first-page":"3817","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.conctc.2020.100678_bib38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s43441-019-00065-7","article-title":"Defining efficacy estimands in clinical trials: examples illustrating ICH E9(R1) guidelines","volume":"54","author":"Ratitch","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.conctc.2020.100678_bib39","first-page":"49583","article-title":"International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice","volume":"63","year":"1998","journal-title":"Fed. Regist."},{"key":"10.1016\/j.conctc.2020.100678_bib40","series-title":"Points to Consider on Switching between Superiority and Non-inferiority","year":"2000"},{"key":"10.1016\/j.conctc.2020.100678_bib41","doi-asserted-by":"crossref","DOI":"10.1046\/j.0306-5251.2001.01397.x","article-title":"Switching between superiority and non-inferiority","volume":"52","author":"Murray","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.conctc.2020.100678_bib42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-1859-x","article-title":"Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review","volume":"18","author":"Althunian","year":"2017","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.conctc.2020.100678_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2018.01.002","volume":"123","author":"Sampayo-Cordero","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.conctc.2020.100678_bib46","article-title":"Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients","volume":"28","author":"Perez-Garcia","year":"2010","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.conctc.2020.100678_bib47","first-page":"3753","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2\u2013positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.conctc.2020.100678_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.conctc.2020.100678_bib49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/sim.717","article-title":"Optimal two-stage designs for clinical trials based on safety and efficacy","volume":"20","author":"Thall","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib50","first-page":"105","article-title":"Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study","volume":"19","author":"Ortega","year":"2019","journal-title":"Clin. Breast Canc."},{"key":"10.1016\/j.conctc.2020.100678_bib51","series-title":"Bayesian Adaptive Methods for Clinical Trials","year":"2011"},{"key":"10.1016\/j.conctc.2020.100678_bib52","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1002\/sim.5477","article-title":"A trivariate continual reassessment method for phase I\/II trials of toxicity, efficacy, and surrogate efficacy","volume":"31","author":"Zhong","year":"2012","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2020.100678_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctrv.2016.10.009","article-title":"Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review","volume":"52","author":"Jardim","year":"2017","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.conctc.2020.100678_bib54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/10543400902802391","article-title":"Between-arm comparisons in randomized phase II trials","volume":"19","author":"Jung","year":"2009","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.conctc.2020.100678_bib55","series-title":"Chapman and Hall\/CRC","article-title":"Randomized phase II cancer clinical trials","author":"Jung","year":"2013"},{"key":"10.1016\/j.conctc.2020.100678_bib56","author":"Sample Size Calculator"},{"key":"10.1016\/j.conctc.2020.100678_bib57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/pst.1983","article-title":"Two\u2010stage phase II survival trial design","volume":"19","author":"Wu","year":"2020","journal-title":"Pharmaceut. Stat."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420301629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420301629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:02:49Z","timestamp":1762520569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865420301629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"alternative-id":["S2451865420301629"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100678","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13821\/v1","asserted-by":"object"}]},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100678"}}